Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Misoprostol or tranexamic acid added to oxytocin versus oxytocin alone for reducing postpartum blood loss after vaginal delivery
TCTR20260226001Phase 3Completed
- Sponsor
- Buddhachinaraj Phitsanulok Hospital
- Start
- May 2025
- Modality
- Recombinant Proteins and Enzymes, Peptides, Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of misoprostol, tranexamic acid, oxytocin in postpartum hemorrhage (PPH), sponsored by Buddhachinaraj Phitsanulok Hospital. Started May 2025; status: completed.
02
Drugs
misoprostoltranexamic acidoxytocin
03
Conditions
postpartum hemorrhage (PPH)
Beyond the preview
Go deeper on TCTR20260226001.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on TCTR20260226001.